Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6053703 | 0.84 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL6053844 | 0.84 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2914122 | 0.84 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12999094 | 0.84 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2HMGCR | |
| SCHEMBL13328653 | 0.83 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2HMGCR | |
| SCHEMBL3142869 | 0.79 | CYP3A4 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL6053776 | 0.73 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL6053775 | 0.73 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL13328639 | 0.73 | CYP3A4 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2ALDH1A1 | |
| SCHEMBL5670862 | 0.72 | CYP3A4 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2010-01-07 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CYP3A4 456/4885HTT 3597/4885SMN1; SMN2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.